Press Releases 

2017

Download
2017/10/11 Adocia announces financial results for the third quarter 2017 Adobe_PDF_Icon.svg
2017/09/05 Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes Adobe_PDF_Icon.svg
2017/07/26 Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer Adobe_PDF_Icon.svg
2017/07/19 Adocia presents first half 2017 financial results Adobe_PDF_Icon.svg
2017/06/07 Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes Adobe_PDF_Icon.svg
2017/06/06 Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes Adobe_PDF_Icon.svg
2017/06/01 Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump Adobe_PDF_Icon.svg
2017/06/01 Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon Adobe_PDF_Icon.svg
2017/05/30 Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions Adobe_PDF_Icon.svg
2017/05/30 Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York Adobe_PDF_Icon.svg
2017/05/19 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris Adobe_PDF_Icon.svg
2017/04/18 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 Adobe_PDF_Icon.svg
2017/04/18 Adocia announces first quarter 2017 financial results Adobe_PDF_Icon.svg
2017/04/13 Number of shares and voting rights of Adocia as of March 31, 2017 Adobe_PDF_Icon.svg
2017/03/21 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2017/03/13 Number of shares and voting rights of ADOCIA as of February 28, 2017 Adobe_PDF_Icon.svg
2017/03/07 ADOCIA announced its financial results for 2016 and its perspectives for 2017 Adobe_PDF_Icon.svg
2017/02/14 Adocia announces its revenue and cash position for 2016 Adobe_PDF_Icon.svg
2017/02/13 Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference Adobe_PDF_Icon.svg
2017/01/27 Adocia to hold conference call on Monday January 30, 2017 Adobe_PDF_Icon.svg
2017/01/27 Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro Adobe_PDF_Icon.svg
2017/01/25 Adocia to hold conference call providing an update on its programs Adobe_PDF_Icon.svg
2017/01/19 Adocia announces the transformation of its business model to increase the value of its projects Adobe_PDF_Icon.svg
2017/01/05 Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes Adobe_PDF_Icon.svg
2017/01/04 Adocia announces its financial calendar for 2017 Adobe_PDF_Icon.svg

2016

Download
2016/12/16 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro Adobe_PDF_Icon.svg
2016/11/10 Adocia to Participate in Upcoming Investor Conferences Adobe_PDF_Icon.svg
2016/11/07 Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes Adobe_PDF_Icon.svg
2016/10/27 Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Adobe_PDF_Icon.svg
2016/10/12 Adocia announces third quarter 2016 financial results Adobe_PDF_Icon.svg
2016/09/22 Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region Adobe_PDF_Icon.svg
2016/09/20 Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes Adobe_PDF_Icon.svg
2016/09/19 Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET) Adobe_PDF_Icon.svg
2016/09/08 Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting Adobe_PDF_Icon.svg
2016/09/07 Adocia announces new BioChaperone program combining a basal insulin and GLP-1s Adobe_PDF_Icon.svg
2016/08/25 Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer Adobe_PDF_Icon.svg
2016/07/20 Adocia presents first half 2016 financial results Adobe_PDF_Icon.svg
2016/07/05 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2016/06/08 Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon Adobe_PDF_Icon.svg
2016/06/06 Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions Adobe_PDF_Icon.svg
2016/06/02 Adocia to Present at the Jefferies 2016 Global Healthcare Conference Adobe_PDF_Icon.svg
2016/05/31 Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Adobe_PDF_Icon.svg
2016/05/13 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Adobe_PDF_Icon.svg
2016/05/03 Adocia strengthens its BioChaperone Combo patent portfolio Adobe_PDF_Icon.svg
2016/04/27 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Adobe_PDF_Icon.svg
2016/04/14 Adocia announces first quarter 2016 results Adobe_PDF_Icon.svg
2016/04/11 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Adobe_PDF_Icon.svg
2016/04/11 Adocia announces the release of its Reference Document, for the year 2015 Adobe_PDF_Icon.svg
2016/03/25 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2016/03/21 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board Adobe_PDF_Icon.svg
2016/03/16 Annual Financial Results 2015 Adobe_PDF_Icon.svg
2016/03/14 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Adobe_PDF_Icon.svg
2016/02/16 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 Adobe_PDF_Icon.svg
2016/02/04 Adocia to Present at the 2016 Leerink Global Healthcare Conference Adobe_PDF_Icon.svg
2016/01/29 Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Adobe_PDF_Icon.svg
2016/01/08 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2015

Download
2015/12/16 Adocia announces its financial calendar for 2016 Adobe_PDF_Icon.svg
2015/12/15 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 Adobe_PDF_Icon.svg
2015/12/11 Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 Adobe_PDF_Icon.svg
2015/11/25 Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes Adobe_PDF_Icon.svg
2015/11/19 Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region Adobe_PDF_Icon.svg
2015/11/04 Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes Adobe_PDF_Icon.svg
2015/10/13 ADOCIA Reports Third Quarter 2015 Financial Results Adobe_PDF_Icon.svg
2015/10/06 Adocia et Lilly initient une étude de phase 1b évaluant l’insuline ultra rapide BioChaperone Lispro chez des patients diabétiques de type 1 utilisant une pompe à insuline Adobe_PDF_Icon.svg
2015/09/30 Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes Adobe_PDF_Icon.svg
2015/08/27 Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Adobe_PDF_Icon.svg
2015/07/21 Adocia presents financial results for the first half of 2015 highlighting strong growth Adobe_PDF_Icon.svg
2015/07/10 Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo Adobe_PDF_Icon.svg
2015/06/26 Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Adobe_PDF_Icon.svg
2015/06/15 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Adobe_PDF_Icon.svg
2015/05/28 Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 Adobe_PDF_Icon.svg
2015/05/26 Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) Adobe_PDF_Icon.svg
2015/05/04 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Adobe_PDF_Icon.svg
2015/04/29 Adocia is now integrated into the EnterNext Tech 40 Index Adobe_PDF_Icon.svg
2015/04/20 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Adobe_PDF_Icon.svg
2015/04/14 Adocia announces first quarter 2015 results Adobe_PDF_Icon.svg
2015/03/16 Adocia will present its 2014 annual results and its perspectives of growth during a conference call Adobe_PDF_Icon.svg
2015/03/10 Adocia reports a strengthened cash position and intensifies clinical development Adobe_PDF_Icon.svg
2015/03/05 Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly Adobe_PDF_Icon.svg
2015/02/17 ADOCIA: annual revenue and net cash position for 2014 Adobe_PDF_Icon.svg
2015/02/10 Adocia: modification of the means allocated to the liquidity agreement Adobe_PDF_Icon.svg
2015/02/05 Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet Adobe_PDF_Icon.svg
2015/01/20 Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation Adobe_PDF_Icon.svg
2015/01/09 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2014

Download
2014/12/29 ADOCIA announces its financial calendar for 2015 Adobe_PDF_Icon.svg
2014/12/22 ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow Adobe_PDF_Icon.svg
2014/12/19 Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology Adobe_PDF_Icon.svg
2014/10/16 ADOCIA Announces Third-quarter Financial 2014 Results Adobe_PDF_Icon.svg
2014/09/30 ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry Adobe_PDF_Icon.svg
2014/09/09 Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes Adobe_PDF_Icon.svg
2014/08/25 Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer Adobe_PDF_Icon.svg
2014/07/24 Adocia Reports Operational and Financial Results for the First Half of 2014 Adobe_PDF_Icon.svg
2014/07/09 Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes Adobe_PDF_Icon.svg
2014/06/24 ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only) Adobe_PDF_Icon.svg
2014/06/16 ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only) Adobe_PDF_Icon.svg
2014/06/10 Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 Adobe_PDF_Icon.svg
2014/06/04 Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014 Adobe_PDF_Icon.svg
2014/05/27 Adocia initiates ADR program in the United States Adobe_PDF_Icon.svg
2014/05/20 Adocia: PR BC Lispro Initiation of phase 2a Adobe_PDF_Icon.svg
2014/05/19 Adocia Press Release Liquidity Agreement with Kepler Adobe_PDF_Icon.svg
2014/05/06 Termination of Liquidity Agreement with DSF Markets Adobe_PDF_Icon.svg
2014/04/10 Adocia: Ultra Fast Lispro Clinical Results Adobe_PDF_Icon.svg
2014/04/10 Adocia: Revenue Q1 2014 Adobe_PDF_Icon.svg
2014/03/26 Gerard Soula Interview – La bourse et la vie (Transcript) Adobe_PDF_Icon.svg
2014/03/20 Adocia: Annual results 2013 Adobe_PDF_Icon.svg
2014/03/17 Adocia: confirmation of positive clinical results Combo Adobe_PDF_Icon.svg
2014/02/26 Positive Clinical Results for Combo Adobe_PDF_Icon.svg
2014/02/10 Adocia: Annual revenue of EUR 5.6 M in 2013 Adobe_PDF_Icon.svg
2014/01/28 Adocia strengthens its diabetic foot ulcer patent portfolio Adobe_PDF_Icon.svg
2014/01/20 Half year report on Adocia’s liquidity agreement at December 2013 Adobe_PDF_Icon.svg
2014/01/06 Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin Adobe_PDF_Icon.svg

2013

Download
2013/12/09 Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors Adobe_PDF_Icon.svg
2013/11/13 Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog Adobe_PDF_Icon.svg
2013/10/24 Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M Adobe_PDF_Icon.svg
2013/10/19 Gérard Soula : interview by Gérald Bouchon, radio Lyon 1ère Adobe_PDF_Icon.svg
2013/09/05 Activity and results for the first half of 2013 Adobe_PDF_Icon.svg
2013/07/29 Adocia reacquires exclusive development rights to ultra-fast acting insulin analog. Adocia and Lilly terminate collaboration Adobe_PDF_Icon.svg
2013/07/15 Half Year report on Adocia’s Liquidity agreement with BIL Finance Adobe_PDF_Icon.svg
2013/04/26 Release of 2012 Reference Document (French only) Adobe_PDF_Icon.svg
2013/04/24 Q1 2013 revenues Adobe_PDF_Icon.svg
2013/04/23 Liquidity agreement Adobe_PDF_Icon.svg
2013/04/23 PR Suspension liquidity agreement Adobe_PDF_Icon.svg
2013/03/18 Adocia announces its phase III development program for the treatment of diabetic foot ulcer. This program has been validated by scientific advice from the European Medicines Agency Adobe_PDF_Icon.svg
2013/02/13 ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 Adobe_PDF_Icon.svg
2013/01/07 Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences Adobe_PDF_Icon.svg

2012

Download
2012/10/30 Adocia announces the strong growth of its turnover Adobe_PDF_Icon.svg
2012/10/22 Adocia is extending its intellectual property to new formulations of monoclonal antibodies Adobe_PDF_Icon.svg
2012/10/01 EASD 2012 – 48th Annual Meeting of the European Association for the Study of Diabetes – 1-5 October 2012, Messe Süd, Berlin, Germany Adobe_PDF_Icon.svg
2012/09/12 Bio India International Conference – 12-13 septembre 2012, Grand Hyatt, Mumbai, Inde Adobe_PDF_Icon.svg
2012/09/07 DFSICON 2012 – 11th Annual Meeting of Diabetic Foot Society of India – 7-9 September 2012, Hyderabad, India Adobe_PDF_Icon.svg
2012/09/03 Financial results and business report for the first half of 2012 Adobe_PDF_Icon.svg
2012/09/02 WUWHS 2012 – 4th Congress of the World Union of Wound Healing Societies – 2-6 September 2012, Yokohama, Japon Adobe_PDF_Icon.svg
2012/06/13 Adocia announces a strengthened intellectual property on its lead project for its chronic wounds treatment Adobe_PDF_Icon.svg
2012/05/30 Additional contribution to Liquidity Agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/04/26 ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 Adobe_PDF_Icon.svg
2012/04/23 ADOCIA reports positive phase II clinical results Adobe_PDF_Icon.svg
2012/04/02 Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA Adobe_PDF_Icon.svg
2012/03/15 Liquidity agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/03/15 ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial… Adobe_PDF_Icon.svg

2017

Download
2017/10/12 Number of shares and voting rights of ADOCIA as of September 30, 2017 Adobe_PDF_Icon.svg
2017/10/11 Adocia announces financial results for the third quarter 2017 Adobe_PDF_Icon.svg
2017/09/18 Number of shares and voting rights of ADOCIA as of August 31, 2017 Adobe_PDF_Icon.svg
2017/07/19 Adocia presents first half 2017 financial results Adobe_PDF_Icon.svg
2017/07/11 Number of shares and voting rights of ADOCIA as of June 30, 2017 Adobe_PDF_Icon.svg
2017/07/10 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2017/06/09 Number of shares and voting rights of ADOCIA as of May 31, 2017 Adobe_PDF_Icon.svg
2017/05/19 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris Adobe_PDF_Icon.svg
2017/04/18 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 Adobe_PDF_Icon.svg
2017/04/18 Adocia announces first quarter 2017 financial results Adobe_PDF_Icon.svg
2017/04/13 Number of shares and voting rights of Adocia as of March 31, 2017 Adobe_PDF_Icon.svg
2017/03/21 ADOCIA confirms its eligibility for the PEA – PME Adobe_PDF_Icon.svg
2017/03/13 Number of shares and voting rights of ADOCIA as of February 28, 2017 Adobe_PDF_Icon.svg
2017/03/07 ADOCIA announced its financial results for 2016 and its perspectives for 2017 Adobe_PDF_Icon.svg
2017/02/14 Adocia announces its revenue and cash position for 2016 Adobe_PDF_Icon.svg
2017/01/19 Adocia announces the transformation of its business model to increase the value of its projects Adobe_PDF_Icon.svg
2017/01/06 Half year report on Adocia’s liquidity agreement with Kepler Chevreux Adobe_PDF_Icon.svg
2017/01/04 Adocia announces its financial calendar for 2017 Adobe_PDF_Icon.svg

2016

Download
2016/10/12 Adocia announces third quarter 2016 financial results Adobe_PDF_Icon.svg
2016/07/20 Adocia presents first half 2016 financial results Adobe_PDF_Icon.svg
2016/05/13 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Adobe_PDF_Icon.svg
2016/05/03 Adocia strengthens its BioChaperone Combo patent portfolio Adobe_PDF_Icon.svg
2016/04/27 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Adobe_PDF_Icon.svg
2016/04/14 Adocia announces first quarter 2016 results Adobe_PDF_Icon.svg
2016/04/11 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Adobe_PDF_Icon.svg
2016/04/11 Adocia announces the release of its Reference Document, for the year 2015 Adobe_PDF_Icon.svg
2016/03/21 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board Adobe_PDF_Icon.svg
2016/03/16 Annual Financial Results 2015 Adobe_PDF_Icon.svg
2016/02/16 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 Adobe_PDF_Icon.svg
2016/01/08 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2015

Download
2015/12/16 Adocia announces its financial calendar for 2016 Adobe_PDF_Icon.svg
2015/12/15 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 Adobe_PDF_Icon.svg
2015/10/13 ADOCIA Reports Third Quarter 2015 Financial Results Adobe_PDF_Icon.svg
2015/10/06 Adocia et Lilly initient une étude de phase 1b évaluant l’insuline ultra rapide BioChaperone Lispro chez des patients diabétiques de type 1 utilisant une pompe à insuline Adobe_PDF_Icon.svg
2015/10/05 Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon Adobe_PDF_Icon.svg
2015/09/17 ADOCIA: additional contribution to the liquidity agreement Adobe_PDF_Icon.svg
2015/07/21 Adocia presents financial results for the first half of 2015 highlighting strong growth Adobe_PDF_Icon.svg
2015/07/07 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2015/06/15 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Adobe_PDF_Icon.svg
2015/05/04 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Adobe_PDF_Icon.svg
2015/04/20 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Adobe_PDF_Icon.svg
2015/04/14 Adocia announces first quarter 2015 results Adobe_PDF_Icon.svg
2015/03/16 Adocia will present its 2014 annual results and its perspectives of growth during a conference call Adobe_PDF_Icon.svg
2015/03/10 Adocia reports a strengthened cash position and intensifies clinical development Adobe_PDF_Icon.svg
2015/02/17 ADOCIA: annual revenue and net cash position for 2014 Adobe_PDF_Icon.svg
2015/02/10 Adocia: modification of the means allocated to the liquidity agreement Adobe_PDF_Icon.svg
2015/01/09 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg

2014

Download
2014/12/29 ADOCIA announces its financial calendar for 2015 Adobe_PDF_Icon.svg
2014/10/16 ADOCIA Announces Third-quarter Financial 2014 Results Adobe_PDF_Icon.svg
2014/07/24 Adocia Reports Operational and Financial Results for the First Half of 2014 Adobe_PDF_Icon.svg
2014/07/10 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Adobe_PDF_Icon.svg
2014/06/24 ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only) Adobe_PDF_Icon.svg
2014/06/16 ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only) Adobe_PDF_Icon.svg
2014/06/10 Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 Adobe_PDF_Icon.svg
2014/05/27 Adocia initiates ADR program in the United States Adobe_PDF_Icon.svg
2014/05/20 Adocia: PR BC Lispro Initiation of phase 2a Adobe_PDF_Icon.svg
2014/05/19 Adocia Press Release Liquidity Agreement with Kepler Adobe_PDF_Icon.svg
2014/05/06 Termination of Liquidity Agreement with DSF Markets Adobe_PDF_Icon.svg
2014/04/10 Adocia: Revenue Q1 2014 Adobe_PDF_Icon.svg
2014/03/20 Adocia: Annual results 2013 Adobe_PDF_Icon.svg
2014/02/10 Adocia: Annual revenue of EUR 5.6 M in 2013 Adobe_PDF_Icon.svg
2014/01/29 2014 Financial Calendar Adobe_PDF_Icon.svg
2014/01/20 Half year report on Adocia’s liquidity agreement at December 2013 Adobe_PDF_Icon.svg

2013

Download
2013/10/24 Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M Adobe_PDF_Icon.svg
2013/09/05 Activity and results for the first half of 2013 Adobe_PDF_Icon.svg
2013/07/15 Half Year report on Adocia’s Liquidity agreement with BIL Finance Adobe_PDF_Icon.svg
2013/04/26 Release of 2012 Reference Document (French only) Adobe_PDF_Icon.svg
2013/04/24 Q1 2013 revenues Adobe_PDF_Icon.svg
2013/04/23 Liquidity agreement Adobe_PDF_Icon.svg
2013/04/23 PR Suspension liquidity agreement Adobe_PDF_Icon.svg
2013/03/20 2012 Annual Results Adobe_PDF_Icon.svg
2013/02/13 ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 Adobe_PDF_Icon.svg
2013/01/07 Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences Adobe_PDF_Icon.svg

2012

Download
2012/10/30 Adocia announces the strong growth of its turnover Adobe_PDF_Icon.svg
2012/09/24 Large & Midcap Event – 24-25 September 2012, Paris Adobe_PDF_Icon.svg
2012/09/04 SFAF meeting – Half year 2012 results. At 14:30, NYSE EURONEXT, room Auditorium – 3 rue Cambon – 75001 Paris Adobe_PDF_Icon.svg
2012/09/03 Financial results and business report for the first half of 2012 Adobe_PDF_Icon.svg
2012/05/30 Additional contribution to Liquidity Agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/04/26 ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 Adobe_PDF_Icon.svg
2012/04/02 Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA Adobe_PDF_Icon.svg
2012/03/15 Liquidity agreement with Dexia Securities France (French only) Adobe_PDF_Icon.svg
2012/03/15 ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial… Adobe_PDF_Icon.svg
TOP